Long acting amylin receptor agonists and uses thereof
The present disclosure relates to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity and/or chronic weight management, dyslipidemia and/or NASH. The disclosure relates to compounds that agonize the amylin receptor and can lower food intake, body weight, glucose and/or triglycerides, so can be used to treat diabetes, obesity, and/or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.
1. A compound comprising SEQ ID NO:2 or a pharmaceutically acceptable salt thereof.
2. A compound comprising SEQ ID NO:4 or a pharmaceutically acceptable salt thereof.
3. A compound comprising SEQ ID NO:6 or a pharmaceutically acceptable salt thereof.
4. A compound comprising SEQ ID NO:8 or a pharmaceutically acceptable salt thereof.
5. A compound consisting of SEQ ID NO:2 or a pharmaceutically acceptable salt thereof.
6. A compound consisting of SEQ ID NO:4 or a pharmaceutically acceptable salt thereof.
7. A compound consisting of SEQ ID NO:6 or a pharmaceutically acceptable salt thereof.
8. A compound consisting of SEQ ID NO:8 or a pharmaceutically acceptable salt thereof.
9. A method of treating Type 2 diabetes in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
10. A method of treating obesity in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
11. A method of treating dyslipidemia in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
12. A method of treating NASH in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
13. A method of lowering food intake by inducing satiety in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 and 1-4 , or a pharmaceutically acceptable salt thereof.
14. A method of lowering body weight by lowering food intake by inducing satiety in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
15. A method of lowering blood glucose in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
16. A method of lowering triglycerides in a patient in need thereof, comprising administering to the patient an effective amount of a compound according to any one of claim 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof.
17. A pharmaceutical composition comprising a compound according to any one of claims 5-8 or 1-4 , or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers, diluents, or excipients.
18. A method of treating a condition in a patient in need thereof, comprising administering to the patient an effective amount of the compound of any one of claims 5-8 or 1-4 and an effective amount of an additional agent, wherein the condition is selected from the group consisting of clinical or pre-clinical diabetes, obesity, NASH, and dyslipidemia.
19. The method of treatment according to claim 18 wherein the additional agent is an incretin or incretin analog.
20. The method of treatment according to claim 19 wherein the incretin or incretin analog is SEQ ID NO:21.